Cellular Therapies for Solid Tumors: The Next Big Thing?January 6, 2025Patient & Survivor CareDLBCLMixed TopicsCellular TherapyBusiness of Medicine
FL: Tafasitamab Plus Combo Boosts OutcomesDecember 18, 2024Non-Hodgkin LymphomaIndolent LymphomaB Cell LymphomaDLBCL
New Cancer Drugs: Do Patients Prefer Faster Access or Clinical Benefit?December 12, 2024Patient & Survivor CareMixed TopicsDLBCLBusiness of MedicineAggressive LymphomasAMLALL
POLARIX: Extended Results Confirm Standard of Care for DLBCLDecember 11, 2024DLBCLNon-Hodgkin LymphomaASH 2024
Epcore NHL-1 Update: Treatment Effective Before CAR TDecember 10, 2024DLBCLB Cell LymphomaNon-Hodgkin LymphomaCellular TherapyASH 2024
LBCL: Bispecific Antibodies Fare Less Well in Real-World AnalysisDecember 9, 2024DLBCLB Cell LymphomaNon-Hodgkin LymphomaPatient & Survivor CareASH 2024
Inside the Patient-Oncologist Bond: Why It’s Often So StrongDecember 2, 2024Patient & Survivor CareMixed TopicsDLBCLMultiple MyelomaAMLAggressive LymphomasALL
For Radiation ‘Downwinders,’ Cancer Compensation Is On HoldOctober 25, 2024Patient & Survivor CareNon-Hodgkin LymphomaMultiple MyelomaDLBCLCMLALLAML
Popular Weight Loss Drugs Now for Patients With Cancer?September 30, 2024Patient & Survivor CareDLBCLAggressive LymphomasALLAMLB Cell LymphomaCLL
Does Medicare Advantage Offer Higher-Value Chemotherapy?September 26, 2024Patient & Survivor CareMixed TopicsBusiness of MedicineALLAggressive LymphomasAMLB Cell Lymphoma
AACR Cancer Progress Report: Big Strides and Big GapsSeptember 26, 2024Patient & Survivor CareDiversity in MedicineDLBCLMixed TopicsPediatricsAggressive LymphomasALL
Cancer Cases, Deaths in Men Predicted to Surge by 2050August 30, 2024Patient & Survivor CareMixed TopicsDLBCLAggressive LymphomasALLAMLB Cell Lymphoma
Cancer Treatment 101: A Primer for Non-OncologistsAugust 23, 2024DLBCLMixed TopicsPatient & Survivor CarePediatricsBusiness of MedicineAggressive LymphomasALL
When Childhood Cancer Survivors Face Sexual ChallengesAugust 22, 2024Mixed TopicsPediatricsPatient & Survivor CareALLCMLCLLHodgkin Lymphoma
Immunotherapy May Be Overused in Dying Patients With CancerAugust 8, 2024DLBCLMixed TopicsPatient & Survivor CarePediatricsAggressive LymphomasALLAML
